Neurexis Therapeutics is Drug Discovery in United States that focus on term health impacts business. Founded in 2020. They cover business area such as developer, therapeutic peptide, brain damage, stroke, an optimize peptide, demonstrate efficacy, two functional domain, patient, a neuroprotective option, long-term health impact.
2020
( 4 years old in 2024 )
Term Health Impacts
-
Bioscience 1, 12635 East Montview Boulevard
Suite 100
Aurora, CO 80045
United States
Private
developertherapeutic peptidebrain damagestrokean optimize peptidedemonstrate efficacytwo functional domainpatienta neuroprotective optionlong-term health impact
* We use standard office opening hours in near Neurexis Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Neurexis Therapeutics is Drug Discovery business from United States that founded in 2020 (4 years old in 2024), Neurexis Therapeutics business is focusing on Term Health Impacts.
Neurexis Therapeutics headquarter office and corporate office address is located in Bioscience 1, 12635 East Montview Boulevard Suite 100 Aurora, CO 80045 United States.
Neurexis Therapeutics was founded in United States.
In 2024, Neurexis Therapeutics is currently focus on term health impacts sector.
Above is snippet of Google Trends for "term health impacts" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Neurexis Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
